Nektar Therapeutics
$ 59.38
0.29%
12 Jun - close price
- Market Cap 2,000,471,000 USD
- Current Price $ 59.38
- High / Low $ 60.75 / 58.88
- Stock P/E N/A
- Book Value 19.55
- EPS -7.93
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.54 %
- 52 Week High 109.00
- 52 Week Low 7.99
About
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Analyst Target Price
$153.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-04 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -1.82 | -1.2898 | -1.87 | -2.95 | -3.61 | -0.15 | -2.65 | -2.81 | -2.76 | -0.22 | -2.85 | -4.05 |
| Estimated EPS | -1.56 | -3.495 | -2.79 | -3.03 | -2.82 | -0.195 | -3.09 | -3.01 | -3.07 | -0.21 | -2.4 | -3.3 |
| Surprise | -0.26 | 2.2052 | 0.92 | 0.08 | -0.79 | 0.045 | 0.44 | 0.2 | 0.31 | -0.01 | -0.45 | -0.75 |
| Surprise Percentage | -16.6667% | 63.0959% | 32.9749% | 2.6403% | -28.0142% | 23.0769% | 14.2395% | 6.6445% | 10.0977% | -4.7619% | -18.75% | -22.7273% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTR
2026-06-11 11:00:00
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics (NASDAQ: NKTR) who bought securities prior to February 26, 2025, and still hold them. The firm is looking into whether Nektar's officers and directors engaged in corporate wrongdoing. Investors are encouraged to visit the firm's website or contact them for more information, with no upfront cost as the firm operates on a contingency fee basis.
2026-06-08 17:09:07
Nektar Therapeutics is initiating its Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis in July 2026, starting with two studies and expecting initial results by mid-2028. This ambitious five-trial program is critical for Nektar's immunology-focused business, especially considering the long development timeline, cash burn, and existing competition in the atopic dermatitis market. The company's future investment narrative and risk profile hinge on the success of these trials and its ability to manage financial resources until potential commercialization.
2026-06-07 18:40:18
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NASDAQ: NKTR) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Nektar securities before February 26, 2025, and continue to hold them, to contact their firm for more information and to assist in the investigation. They operate on a contingency fee basis, meaning investors incur no upfront costs.
2026-06-06 21:10:04
This article displays the inventory turnover data for Nektar Therapeutics (XETR:ITH0). It presents a table with "Period," "Value," "Change," and "Change %" columns. The information is sourced from ICE Data Services, FactSet, and Quartr.
2026-06-06 18:09:07
Nektar Therapeutics (NKTR) has seen a significant share price pullback recently, despite strong year-to-date and one-year returns. The article highlights that Nektar is considered 62.6% undervalued with a narrative fair value of $153.25 against its current trading price of $57.32, driven by promising Phase IIb data for REZPEG. However, it also points out the company's high P/S ratio of 34.8x compared to the industry average, suggesting a high valuation risk despite potential future growth.
2026-06-06 17:09:40
Nektar Therapeutics reported the results of its Annual Meeting of Stockholders held on June 4, 2026, including the re-election of directors and the ratification of Ernst & Young LLP as its independent auditor. A key outcome was the approval of an amendment to the Performance Incentive Plan, increasing authorized common shares by 3,000,000, which offers flexibility for talent retention but also introduces potential shareholder dilution. The company's common stock continues to be listed on the Nasdaq Capital Market under the ticker NKTR.
